Literature DB >> 22678721

Dynamic reduction of plasma decorin following ischemic stroke: a pilot study.

Yuan-Zhi Xu1, Zhi-Gang Yang, Yu-Hui Zhang, Yong-Wei Zhang, Bo Hong, Jian-Min Liu.   

Abstract

The aim of this study was to investigate the dynamic changes in plasma decorin concentration after acute ischemic stroke and to study its relationship with clinical stroke subtypes. We collected three plasma samples from patients with acute ischemic stroke (n = 35) and controls (n = 30): upon admission (1-3 days) between 3 days and 1 week (3-7 days), and between 7 days and 2 weeks (7-14 days). The relationship between Decorin concentration and Trial of ORG10172 in Acute Stroke Treatment (TOAST) subtypes and outcomes were evaluated. The concentration of decorin gradually decreased following the onset of stroke at all different time-points (<3 days, p < 0.05; 3-7 days, p < 0.01; and 7-14 days, p < 0.01) compared to controls. The level of decorin at 7-14 days is significantly lower than that at <3 days (p < 0.01) in the stroke patients. Decorin levels were lower in the Large-artery atherosclerosis group than the rest of the TOAST subgroups (p = 0.024). Decorin levels decreased more in the patients with poor outcome (mRS 3-6) than those with favorable outcome (mRS 0-2, p < 0.05) at a time-point of 3-7 days. There is a dynamic reduction in Decorin level the days following ischemic stroke, and the decrement persists at least the first 2 weeks. The dynamic reduction of decorin might indicate that decorin is concomitantly involved in the pathophysiological processes of stroke. Larger studies are needed to confirm whether decorin is a useful marker of stroke and a prognostic indicator of outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678721     DOI: 10.1007/s11064-012-0787-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage.

Authors:  Christian Schachtrup; Jae K Ryu; Matthew J Helmrick; Eirini Vagena; Dennis K Galanakis; Jay L Degen; Richard U Margolis; Katerina Akassoglou
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 2.  Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction.

Authors:  Liliana Schaefer; Renato V Iozzo
Journal:  J Biol Chem       Date:  2008-05-06       Impact factor: 5.157

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J M Bamford; P A Sandercock; C P Warlow; J Slattery
Journal:  Stroke       Date:  1989-06       Impact factor: 7.914

4.  Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain.

Authors:  B Merle; L Durussel; P D Delmas; P Clézardin
Journal:  J Cell Biochem       Date:  1999-12-01       Impact factor: 4.429

5.  Decorin, a novel player in the insulin-like growth factor system.

Authors:  Elke Schönherr; Cord Sunderkötter; Renato V Iozzo; Liliana Schaefer
Journal:  J Biol Chem       Date:  2005-02-08       Impact factor: 5.157

6.  Standard method for developing stroke registers in low-income and middle-income countries: experiences from a feasibility study of a stepwise approach to stroke surveillance (STEPS Stroke).

Authors:  T Truelsen; P U Heuschmann; R Bonita; G Arjundas; P Dalal; A Damasceno; D Nagaraja; A Ogunniyi; S Oveisgharan; K Radhakrishnan; V I Skvortsoya; V Stakhovskaya
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

7.  Decorin is a biological ligand for the epidermal growth factor receptor.

Authors:  R V Iozzo; D K Moscatello; D J McQuillan; I Eichstetter
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

8.  Focal cerebral ischemia induces active proteases that degrade microvascular matrix.

Authors:  Shunichi Fukuda; Catherine A Fini; Takuma Mabuchi; James A Koziol; Leonard L Eggleston; Gregory J del Zoppo
Journal:  Stroke       Date:  2004-03-04       Impact factor: 7.914

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  [Effects of overexpression of decorin on matrix metalloproteinases 2 and 9 in rat mesangial and tubular cells].

Authors:  Feng-qin Dong; Hong Li; Fang Wu; Hang-ping Yao
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2008-12-30
View more
  5 in total

1.  Decorin causes autophagy in endothelial cells via Peg3.

Authors:  Simone Buraschi; Thomas Neill; Atul Goyal; Chiara Poluzzi; James Smythies; Rick T Owens; Liliana Schaefer; Annabel Torres; Renato V Iozzo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

Review 2.  Decorin as a multivalent therapeutic agent against cancer.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Adv Drug Deliv Rev       Date:  2015-10-30       Impact factor: 15.470

3.  Possible dual role of decorin in abdominal aortic aneurysm.

Authors:  Koshiro Ueda; Koichi Yoshimura; Osamu Yamashita; Takasuke Harada; Noriyasu Morikage; Kimikazu Hamano
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 4.  Proteoglycan form and function: A comprehensive nomenclature of proteoglycans.

Authors:  Renato V Iozzo; Liliana Schaefer
Journal:  Matrix Biol       Date:  2015-02-18       Impact factor: 11.583

Review 5.  Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest.

Authors:  Dorin Harpaz; Evgeni Eltzov; Raymond C S Seet; Robert S Marks; Alfred I Y Tok
Journal:  Biosensors (Basel)       Date:  2017-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.